Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16865380 | 1.00 | KLK5 (0.46) | KLK5PPARAPPARGCTSSCTSK | |
| SCHEMBL16865381 | 0.89 | SPHK1 (0.42) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865379 | 0.89 | SPHK1 (0.42) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865349 | 0.89 | SPHK1 (0.42) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865351 | 0.88 | PPARA (0.43) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865382 | 0.88 | PPARA (0.43) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865332 | 0.88 | PPARA (0.43) | KLK5PPARAPPARGCTSKSPHK1 | |
| SCHEMBL16865383 | 0.84 | PPARG (0.46) | PPARAPPARGSPHK1MAPT | |
| SCHEMBL13986003 | 0.82 | TDP1 (0.47) | KLK5PPARAPPARGCTSSCTSK | |
| SCHEMBL20651355 | 0.82 | SPHK1 (0.65) | PPARAPPARGCTSKSPHK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133488-B2 | Synthetic methods and compounds related thereto | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133488-B2 | Synthetic methods and compounds related thereto | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150184206-A1 | SYNTHETIC METHODS AND COMPOUNDS RELATED THERETO | UNIVERSITY OF ALASKA FAIRBANKS | 2015-07-02 | — | — | US | disclosed |
| US-20150184206-A1 | SYNTHETIC METHODS AND COMPOUNDS RELATED THERETO | UNIVERSITY OF ALASKA FAIRBANKS | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150184206-A1 | SYNTHETIC METHODS AND COMPOUNDS RELATED THERETO | LSS, CYP51A1, FASN | KLK5 2560/4885PPARA 191/4885PPARG 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.